Answers are grounded in this paper and cite their sources.
Psychometric evaluation demonstrates strong validity and reliability for the Dimensional Anhedonia Rating Scale in co-occurring depression and cannabis use disorder, highlighting its clinical utility.
Aim: Anhedonia is a transdiagnostic symptom of major depressive disorder (MDD) that is also influenced by substance use, yet the Dimensional Anhedonia Rating Scale (DARS) has only been validated in MDD. This study examined the psychometric properties of the DARS in co-occurring MDD and cannabis use disorder (CUD). Methods: Thirty-five participants completed the DARS, Snaith–Hamilton Pleasure Scale (SHAPS), Hamilton Rating Scale for Depression (HRSD), Beck Depression Inventory (BDI), and Beck Anxiety Inventory (BAI). Analyses included confirmatory factor analysis, internal consistency, Spearman correlations, group comparisons, and ROC analysis against SHAPS-defined anhedonia. Results: The DARS supported a four-factor (and second-order) structure, demonstrated excellent internal consistency, and showed expected convergent validity (e.g., SHAPS ρ=−.64). ROC analysis indicated good discrimination (AUC=.81) with a Youden-derived threshold of 65 (sensitivity ≈.85; specificity ≈.75). Conclusions: This study provides preliminary evidence of the utility of the DARS in co-occurring MDD and CUD.
No takes yet. Share an insight, caveat, or question.
Grant et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: